Registry as a tool for monitoring effectiveness of immunobiological therapy for severe asthma in real clinical practice

Registry is a unique and universal mechanism for group and individual approaches to managing patients, including those with severe asthma (SA) who require targeted therapy.

The aim is to evaluate the clinical and organizational potential of the SA patient registry as a tool for group and individual approaches to patient management, as a way to describe and systematize the signs of bronchial asthma, comorbid diseases, and monitoring immunobiological therapy (using anti-IgE therapy as an example) in patients with SA in Sverdlovsk region.

Methods. The subject of the study was the Territorial Registry of Patients with SA of the Sverdlovsk region. The registry effectiveness was assessed based on the clinical and organizational indicators, including monitoring the effectiveness of 3-year anti-IgE therapy in patients with SA with an allergic component.

Results. From 2016 to 2023, both inclusive, 198 patients with SA were entered into the registry. Analysis of the registry data allowed us to develop a scheme for SA phenotyping and selecting the 1st and 2^nd line targeted drugs and a scheme for phenotyping and selecting a targeted drug for T2 inflammatory nasal diseases. Over 3 years of anti-IgE therapy with omalizumab, the ACT test increased from 9.00 to 19.50 points, the proportion of patients with partial and good asthma control increased by 13.89 times, the frequency of exacerbations decreased by 71.43%, FEV1 increased by 17.91%, and the proportion of patients requiring systemic corticosteroids decreased by 83.32%.

Conclusion. The registry of SA patients has high clinical and organizational potential to describe and systematize the signs of bronchial asthma, comorbid diseases, and monitor the effectiveness and safety of immunobiological therapy. The 3-year anti-IgE therapy demonstrates statistically significant effectiveness in patients with SA with an allergic component.

1. Ministry of Health of the Russian Federation. [Guidelines: Bronchial asthma]. 2021. Available at: https://cr.minzdrav.gov.ru/schema/359_2 [Accessed: October 26, 2024] (in Russian).

2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2024. Available at: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf [Accessed: October 26, 2024].

3. Goldina T.A., Kolbin A.S., Belousov D.Yu., Borovskaya V.G. [Review of real-world data study]. Kachestvennaya klinicheskaya praktika. 2021; (1): 56–63. DOI: 10.37489/2588-0519-2021-1-56-63 (in Russian).

4. Ivanov A.V., Semykin V.N. [Maintaining patient registries, on the basis of which regulatory authorities can make decisions regarding medicines]. Real'naya klinicheskaya praktika: dannye i dokazatel'stva. 2023; 3 (1): 41–50. DOI: 10.37489/2782-3784-myrwd-30 (in Russian).

5. Yagudina R. I., Litvinenko M.M., Sorokovikov I.V. [Patient registers: structure, function, use]. Farmakoekonomika. 2011; (4): 3–7 Available at: https://cyberleninka.ru/article/n/registry-patsientov-struktura-funktsii-vozmozhnosti-ispolzovaniya (in Russian).

6. Beltyukov Е.K., Shelyakin V.A., Naumova V.V. et al. [Organization of immunobiological therapy for severe bronchial asthma in the Sverdlovsk region]. Rossiyskiy allergologicheskiy zhurnal. 2021; 18 (1): 6–17. DOI: 10.36691/RJA1414 (in Russian)

7. Naumova V.V., Beltyukov E.K., Kovtun O.P. et al. [Clinical and allergological characteristics of patients with severe bronchial asthma in the regional registry and phenotyping principles for the targeted therapy choice]. Meditsinskiy sovet. 2024; 18 (9): 47–61. 10.21518/ms2024-177 (in Russian).

8. Naumova V.V., Beltyukov E.K., Abdullaev V.Ch. et al. [Efficacy of two-year anti-IgE therapy in patients with severe allergic bronchial asthma in Sverdlovsk region]. Meditsinskiy sovet. 2023; 17 (4): 8–17. DOI: 10.21518/ms2023-050 (in Russian).

9. Naumova V.V., Beltyukov Е.К., Kovtun О.P. et al. [Direct comparative study of anti-IgE and anti-IL4Rα therapy effectiveness in patients with severe allergic and mixed bronchial asthma]. Meditsinskiy sovet. 2024; 18 (9): 74–86. DOI: 10.21518/ms2024-195 (in Russian).

10. Naumova V.V., Beltyukov Е.К., Kovtun О.P. et al. [Direct comparative study of the effectiveness of mepolizumab and dupilumab in patients with severe non-allergic eosinophilic asthma]. Meditsinskiy sovet. 2023; 17 (20): 16–25. DOI: 10.21518/ms2023-308 (in Russian).

11. Naumova V.V., Beltyukov E.K., Kiseleva D.V. [Efficacy of anti-IL-5 therapy with mepolizumab for severe bronchial asthma and concomitant inflammatory nasal diseases in real clinical practice]. Rossiyskiy allergologicheskiy zhurnal. 2022; 19 (1): 67–79. DOI: 10.36691/RJA1519 (in Russian).

12. Naumova V.V., Kiseleva D.V., Beltyukov E.K., Starikova Ya.R. [Anti-IL-4, 13 strategy in management of comormid patients in the regional register of severe bronchial asthma]. Rossiyskiy allergologicheskiy zhurnal. 2022; 19 (4): 435–446. DOI: 10.36691/RJA1580 (in Russian).

13. Naumova V.V., Beltyukov E.K., Kiseleva D.V. et al. [Targeted therapy for severe asthma: switching biological agents in real clinical practice, causes, and consequences]. Rossiyskiy allergologicheskiy zhurnal. 2023; 20 (4): 439–454. DOI: 10.36691/RJA15993 (in Russian).

14. van Bragt J.J.M.H., Adcock I.M., Bel E.H.D. et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur. Respir. J. 2020; 55 (1): 1901163. DOI: 10.1183/13993003.01163-2019.

15. Cushen B., Koh M.S., Tran T.N. et al. Adult severe asthma registries: a global and growing inventory. Pragmat. Obs. Res. 2023; 14: 127–147. DOI: 10.2147/POR.S399879.

16. Park S.Y., Fowler S., Shaw D.E. et al. Comparison of asthma phenotypes in severe asthma cohorts (SARP, U-BIOPRED, ProAR and COREA) from 4 continents. Allergy Asthma Immunol. Res. 2024; 16 (4): 338–352. DOI: 10.4168/aair.2024.16.4.338.

17. Belevskiy A.S., Nenasheva N.M., Kravchenko N.Yu. et al. [Data from the Russian severe asthma registry (RSAR)]. Terapevticheskiy arkhiv. 2022; 94 (7): 865–871. DOI: 10.26442/00403660.2022.07.201713 (in Russian).

18. Fomina D.S., Mukhina O.A., Lebedkina M.S. et al. [Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice]. Terapevticheskiy arkhiv. 2022; 94 (3): 413–419. DOI: 10.26442/00403660.2022.03.201437 (in Russian).

19. Fomina D.S., Mukhina O.A., Lebedkina M.S. et al. [Registry analysis of patients with severe allergic asthma and clinically relevant sensitization to fungal allergens treated with genetically engineered biologics]. Consilium Medicum. 2022; 24 (3): 170–176. DOI: 10.26442/20751753.2022.3.201442 (in Russian).

20. Vishneva E.A., Namazova-Baranova L.S., Dobrynina E.A. et al. [The long-term Omalizumab therapy in children with severe persistent uncontrolled asthma: evaluation of the outcomes according to the data of the hospital patient registry. Pediatricheskaya farmakologiya. 2018; 15 (2): 149–158. DOI: 10.15690/pf.v15i2.1877 (in Russian).

21. Grimaldi-Bensouda L., Zureik M., Aubier M. et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013; 143 (2): 398–405. DOI: 10.1378/chest.12-1372.

22. Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the “real-world” effectiveness of Omalizumab in allergic asthma. Respir. Med. 2013; 107 (8): 1141–1151. DOI: 10.1016/j.rmed.2013.04.017.

23. Eisner M.D., Zazzali J.L., Miller M.K. et al. Longitudinal changes in asthma control with Omalizumab: 2-year interim data from the EXCELS study. J. Asthma. 2012; 49 (6): 642–648. DOI: 10.3109/02770903.2012.690477.

24. Vennera M.C., Pérez D.L.L., Bardagí S. et al. Omalizumab therapy in severe asthma: experience from the Spanish registry – some new approaches. J. Asthma. 2012; 49 (4): 416–422. DOI: 10.3109/02770903.2012.668255.

25. Long A., Rahmaoui A., Rothman K.J. et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without Omalizumab. J. Allergy Clin. Immunol. 2014; 134 (3): 560–567.e4. DOI: 10.1016/j.jaci.2014.02.007.

26. MacDonald K.M., Kavati A., Ortiz B. et al. Shortand long-term real-world effectiveness of Omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev. Clin. Immunol. 2019; 15 (5): 553–569. DOI: 10.1080/1744666X.2019.1574571.

27. López T.J.J., Contreras E.A., del Pozo M.E. et al. Real life study of three years Omalizumab in patients with difficult-to-control asthma. Allergol. Immunopathol. (Madr.). 2015; 43 (2): 120–126. DOI: 10.1016/j.aller.2013.11.008.

28. Dal Negro R.W., Tognella S., Pradelli L. A 36-month study on the cost/utility of add-on Omalizumab in persistent difficult-to-treat atopic asthma in Italy. J. Asthma. 2012; 49 (8): 843–848. DOI: 10.3109/02770903.2012.717659.

29. Özgür E.S., Özge C., Ïlvan A., Naycı S.A. Assessment of long-term Omalizumab treatment in patients with severe allergic asthma long-term Omalizumab treatment in severe asthma. J. Asthma. 2013; 50 (6): 687–694. DOI: 10.3109/02770903.2013.792348.

30. Tzortzaki E.G., Georgiou A., Kampas D. et al. Long-term Omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean “real-life” experience. Pulm. Pharmacol. Ther. 2012; 25 (1): 77–82. DOI: 10.1016/j.pupt.2011.11.004.